We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 15, 2021

Neoadjuvant Nivolumab for High-Risk Nonmetastatic Renal Cell Carcinoma

European Urology Oncology


Additional Info

European Urology Oncology
Neoadjuvant Nivolumab in Patients With High-Risk Nonmetastatic Renal Cell Carcinoma
Eur Urol Oncol 2021 May 25;[EPub Ahead of Print], MA Gorin, HD Patel, SP Rowe, NM Hahn, HJ Hammers, A Pons, BJ Trock, PM Pierorazio, TR Nirschl, DC Salles, JE Stein, TL Lotan, JM Taube, CG Drake, ME Allaf

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading